PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
出版年份 2021 全文链接
标题
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2021-06-05
DOI
10.1093/jnci/djab108
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
- (2021) Leisha A Emens et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- (2020) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
- (2020) Emily S. Reisenbichler et al. MODERN PATHOLOGY
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
- (2019) Dennis P. O’Malley et al. MODERN PATHOLOGY
- 10OComparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)
- (2019) M Scott et al. ANNALS OF ONCOLOGY
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
- (2019) Emina Torlakovic et al. MODERN PATHOLOGY
- 1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
- (2019) M Reck et al. ANNALS OF ONCOLOGY
- LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
- (2019) J Cortés et al. ANNALS OF ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- PD-L1 in breast cancer: comparative analysis of 3 different antibodies
- (2018) Tejashree Karnik et al. HUMAN PATHOLOGY
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
- (2018) Shona Hendry et al. Journal of Thoracic Oncology
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
- (2018) Peter Savas et al. NATURE MEDICINE
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- (2018) Bharathi Vennapusa et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Atezolizumab for the treatment of triple-negative breast cancer
- (2018) Anne-Sophie Heimes et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
- (2018) Marcin Kowanetz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
- (2017) Haipeng Xu et al. Scientific Reports
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started